EVAX News

Evaxion announces 89% vaccine target precision and sustained T-cell and clinical responses at three-year follow-up in phase 2 trial with personalized cancer vaccine EVX-01

Evaxion reports sustained clinical responses for all patients at three-year follow-up in phase 2 trial with personalized cancer vaccine EVX-01

Evaxion will present new immune data for personalized cancer vaccine EVX-01 at the SITC 2026 Annual Meeting

Evaxion applies its AI-Immunology™ platform in autoimmune diseases

Evaxion announces business update and second quarter 2026 financial results

Evaxion expands and refocuses R&D pipeline with EVX-05, an AI-designed off-the-shelf brain cancer vaccine program

Evaxion to announce business update and second quarter 2026 financial results on August 20, 2026

Evaxion to present three-year clinical efficacy data for personalized cancer vaccine EVX-01 at the ESMO Congress 2026

Evaxion presents new preclinical data for cytomegalovirus vaccine program EVX-V1

Evaxion to present new preclinical data for cytomegalovirus vaccine candidate EVX-V1 at the International Herpesvirus Workshop